YOLFTbeta
S2Medical AB

S2Medical AB

S2M · ST · Healthcare / Medical Instruments & Supplies

0.0034SEK+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.0034
Open0.0034
Day Range0.0032 – 0.0034
52-Week Range0.0032 – 0.0128
Volume3.90M
Market Cap4.39M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.01
Dividend Yield0.00%
Beta2.33
50-Day Avg0.0055
200-Day Avg0.0074

About

S2Medical AB (publ) develops products for wound healing, infection control, and cosmeceuticals spectrum in Sweden. The company offers odor eliminator under the YNOLENS brand; IvaQ, a negative pressure wound therapy (NPWT) system; Instagraft, a technology designed to make skin transplantation even in non-specialist healthcare setting; ADMERCIN, a solution against antibiotic-resistant bacteria; and Epiprotect, a technology designed to protect and support wound healing by creating an environment for tissue recovery. It also provides Symbiovance, a peptide-based functional skincare; Eyracure, a light-activated peptide technology that repairs damaged hair at the molecular level; and Eiratex, a biosynthetic polymer for wound healing applications. In addition, the company distributes instaQrett; skin substitutes under the EPIPROTECT brand; and BIOPAD, an ivory-white soft sponge. The company was incorporated in 2013 and is headquartered in Linköping, Sweden.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOMr. Petter Sivler
  • Employees10
  • HeadquartersSunnorpsgatan 5, Linköping, Sweden, 582 73, Sweden
  • Websitehttps://www.s2m.se

Leadership

  • Mr. Petter SivlerCo-Founder & CEO · b. 1985
  • Mr. Marten SkogCo-Founder, COO & Director · b. 1982

Financials

Income Statement

Currency: SEK2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.53M340.00K844.00K1.50M3.10M25.62M7.70M4.67M6.97M14.91M14.36M
Growth (%)--77.84%+148.24%+77.20%+107.17%+726.72%-69.94%-39.35%+49.27%+113.82%-3.66%
Cost of Revenue689.93K-2.24M-1.05M-3.27M-804.54K15.57M602.80K-494.85K1.93M766.00K16.43M
Gross Profit844.60K2.58M1.90M4.77M3.90M10.05M7.10M5.17M5.04M14.14M-2.07M
Gross Margin55.04%758.24%224.76%318.90%125.97%39.23%92.17%110.60%72.25%94.86%-14.39%
Operating Expense773.83K3.63M7.12M15.38M22.24M25.11M26.93M32.85M20.30M8.35M614.89K
Operating Income70.77K-1.05M-5.22M-10.61M-18.33M-15.06M-19.84M-27.69M-15.26M5.79M-2.68M
Operating Margin4.61%-308.24%-618.96%-709.19%-591.73%-58.80%-257.62%-592.88%-218.95%38.85%-18.67%
EBITDA141.89K-825.00K-4.57M-9.78M-17.45M-14.14M-18.73M-26.37M-13.53M6.82M-1.41M
EBITDA Margin9.25%-242.65%-541.77%-654.05%-563.22%-55.20%-243.22%-564.56%-194.08%45.77%-9.78%
Net Income2.80K-1.20M-5.38M-10.73M-18.44M-15.08M-20.08M-29.46M-22.71M5.77M-10.09M
Net Income Margin0.18%-351.47%-637.09%-717.50%-595.00%-58.88%-260.78%-630.73%-325.73%38.72%-70.27%
R&D--383.74K383.74K383.74K383.74K385.34K594.90K606.11K--
R&D as % of Total Revenue--45.47%25.66%12.38%1.50%5.00%12.74%8.69%--
Interest Expense-147.00K153.00K124.27K101.29K73.05K243.41K1.77M7.44M20.00K6.00K
Interest Expense % of Total Revenue-43.24%18.13%8.31%3.27%0.29%3.16%37.85%106.78%0.13%0.04%

Balance Sheet

Currency: SEK2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets3.50M6.43M11.17M49.08M30.71M41.24M29.68M25.29M21.41M18.09M16.90M
Total Liabilities3.46M3.67M3.80M5.53M5.60M8.48M15.00M18.22M19.75M6.29M7.03M
Total Equity36.05K2.75M7.38M43.55M25.11M32.77M14.68M7.07M1.66M11.80M9.88M
Cash1.49M1.97M5.49M36.44M15.46M25.32M9.48M3.72M1.52M1.00M907.00K
Total Debt3.00M-165.29K2.24M1.51M830.77K207.69K----
Net Debt1.51M-1.97M-5.33M-34.20M-13.95M-24.49M-9.27M-3.72M-1.52M-1.00M-907.00K

Cash Flow

Currency: SEK2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow--3.03M-5.85M-12.75M-17.10M-12.75M-19.67M-28.13M-16.52M5.03M675.00K
Investing Cash Flow--611.00K-475.00K-2.57M-3.15M-1.98M-3.02M-1.76M-1.15M-634.00K-2.02M
Financing Cash Flow-4.12M9.84M46.27M-728.22K24.41M6.85M24.14M15.47M-5.54M1.25M
Capital Expenditure0611.00K475.00K2.57M3.15M1.98M3.10M1.90M1.15M634.00K675.00K
Free Cash Flow--3.64M-6.32M-15.33M-20.25M-14.73M-22.76M-30.03M-17.67M2.49M-1.35M
FCF to OCF-120.16%108.13%120.18%118.39%115.52%115.75%106.75%106.99%49.46%-199.71%

Earnings

Report DateDec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Jun 7, 2024Jun 30, 2024
EPS Estimate-----------------------
EPS Actual-0.01-0.05-0.07-0.04-0.07-0.060.00-0.06-0.06-0.04-0.04-0.05-0.06-0.08-0.07-0.06-0.05-0.03-0.15-0.02-0.010.000.01
Surprise-----------------------
Timing---------------------Pre-market-

Key Statistics & Ratios

Market Cap4.39M
Enterprise Value6.02M
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.30
Price / Book0.65
EPS-0.01
Book Value0.011
Revenue (TTM)14.90M
Gross Profit (TTM)13.18M
EBITDA-1.36M
Profit Margin-67.61%
Operating Margin2.53%
Return on Equity-69.59%
Return on Assets-5.64%
Shares Outstanding1.21B
Shares Float836.14M
Beta2.33
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Aug 19, 202631:23
  • Aug 30, 202461:47
  • Jun 14, 2023171:59
  • Apr 19, 202242:31
  • Nov 17, 2020160:153